Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

0.6332 +0.0032 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Path Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
BPTH Stock Earnings: Bio-Path Holdings Misses EPS for Q1 2024
BPTH stock results show that Bio-Path Holdings missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Bio-Path Holdings Reports First Quarter 2024 Financial Results
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Looking Into Bio-Path Hldgs's Recent Short Interest
Via Benzinga
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Why Bio-Path Stock Is Soaring
Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
Walgreens layoffs are in the news Thursday after the pharmacy chain announced plans to cut jobs in Chicago while reducing employees' hours. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Bio-Path Holdings Inc. (NASDAQ: BPTH) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe stock is rallying on Wednesday after the company's CEO announced plans to take ME shares private in a potential deal. 
Via InvestorPlace
Why Is Bio-Path (BPTH) Stock Up 89% Today?
Bio-Path stock is up with heavy trading of BPTH shares today alongside positive news from its ongoing clinical trial of BP1002. 
Via InvestorPlace
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 37,880.89 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Expands Global Patent Portfolio
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several Milestones 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning! 
Via InvestorPlace
Why Bio-Path Holdings Shares Are Falling Today
Bio-Path reported a net loss of $33.63 per share for the year ended Dec. 31, 2023, lower than $38.12 per share in the year-ago period. 
Via Benzinga
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Earnings Scheduled For March 8, 2024
Companies Reporting Before The Bell • Algonquin Power (NYSE:AQN) is likely to report quarterly earnings at $0.14 per share on revenue of $743.00 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.